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Background: Mitochondrial myopathies (MM) are a heterogeneous group of inherited conditions resulting
from a primary defect in the mitochondrial respiratory chain with consecutively impaired cellular energy
metabolism. Small sized studies using mainly electrocardiography (ECG) and echocardiography have revealed
cardiac abnormalities ranging from conduction abnormalities and arrhythmias to hypertrophic or dilated
cardiomyopathy in these patients. Recently, characteristic patterns of cardiac involvement were documented
by cardiovascular magnetic resonance (CMR) in patients with chronic progressive external ophthalmoplegia
(CPEO)/Kearns-Sayre syndrome (KSS) and with mitochondrial encephalopathy with lactic acidosis and stroke-
like episodes (MELAS). The present study aimed to characterize the prevalence and pattern of cardiac
abnormalities and to test the additional diagnostic value of CMR in this patient population. The hypothesis
that different neuromuscular MM syndromes present with different cardiac disease phenotypes was
evaluated.
Methods: Sixty-four MM patients (50 ± 15 years, 44 % male) and 25 matched controls (52 ± 14 years, 36 % male)
prospectively underwent cardiac evaluations including CMR (comprising cine- and late-gadolinium-enhancement (LGE)
imaging). Based on the neuromuscular phenotype and genotype, the patients were grouped: a) CPEO/KSS (N = 33); b)
MELAS/–like (N = 11); c) myoclonic epilepsy with ragged-red fibers (MERRF) (N = 3) and d) other non-specific MM
forms (N = 17).
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Results: Among the 64 MM patients, 34 (53 %) had at least one abnormal CMR finding: 18 (28 %) demonstrated an
impaired left ventricular ejection-fraction (LV-EF <60 %), 14 (22 %) had unexplained LV hypertrophy and 21 (33 %)
were LGE-positive. Compared to controls, MM patients showed significantly higher maximal wall thickness (10 ± 3
vs. 8 ± 2 mm, p = 0.005) and concentricity (LV mass to end-diastolic volume: 0.84 ± 0.27 vs. 0.67 ± 0.11, p < 0.0001)
with frequent presence of non-ischemic LGE (30 % vs. 0 %, p = 0.001). CPEO/KSS showed a predominantly intramural
pattern of LGE mostly confined to the basal LV inferolateral wall (8/10; 80 %) in addition to a tendency toward concentric
remodelling. MELAS/-like patients showed the highest frequency of cardiac disease (in 10/11 (91 %)), a mostly concentric
LV hypertrophy (6/9; 67 %) with or without LV systolic dysfunction and a predominantly focal, patchy LGE equally
distributed among LV segments (8/11; 73 %). Patients with MERRF and non-specific MM had no particular findings.
Pathological CMR findings indicating cardiac involvement were detected significantly more often than pathological
ECG results or elevated cardiac serum biomarkers (34 (53 %) vs. 18 (28 %) vs. 21 (33 %); p = 0.008).
Conclusion: Cardiac involvement is a frequent finding in MM patients – and particularly present in KSS/CPEO as well
as MELAS/-like patients. Despite a high variability in clinical presentation, CPEO/KSS patients typically show an
intramural pattern of LGE in the basal inferolateral wall whereas MELAS patients are characterized by overt concentric
hypertrophy and a rather unique, focally accentuated and diffusely distributed LGE.
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Mitochondrial myopathies (MM) are a heterogeneous
group of inherited conditions resulting from a primary
defect in the mitochondrial respiratory chain with con-
secutively impaired cellular energy metabolism affecting
multiple organ systems. Despite the high variability in
clinical presentation and the poor genotype-phenotype
correlation, several syndromes with characteristic symp-
toms have been defined [1]. These disorders have a pro-
gressive course associated with different degrees of
neurological disability and in some instances with pre-
mature death primarily due to cardiac and neurological
adverse events [2–5].
The overall prevalence of MM-related cardiomyopathy
is difficult to estimate and varies according to syndrome
and to the diagnostic approach used [6, 7]. Cardiac ab-
normalities ranging from preexcitation, conduction
blocks and arrhythmias to dilated or hypertrophic car-
diomyopathy phenotypes have been described in several
syndromes like chronic progressive external ophthalmo-
plegia (CPEO), Kearns-Sayre syndrome (KSS), mito-
chondrial encephalopathy with lactic acidosis and
stroke-like episodes (MELAS), myoclonic epilepsy with
ragged-red fibers (MERRF) and Leigh syndrome. These
data derive from case reports and small sized studies
using mainly electrocardiography (ECG) and echocardi-
ography for cardiac evaluation [2, 4, 5, 8–12].
Cardiovascular magnetic resonance (CMR) is a highly
sensitive tool for depicting myocardial abnormalities in
MM patients including tissue damage by late gadolinium
enhancement (LGE) [13–16]. Recently, two small sized
CMR studies suggested that characteristic patterns of
cardiac involvement might be present in some of the
above syndromes [17, 18]. As no disease modifying therapyexists, an early diagnosis of cardiac involvement – particu-
larly by CMR studies - would permit a timely initiation of
appropriate treatment strategies with potential improve-
ment in patient prognosis [19].
The present study aimed to characterize the preva-
lence and pattern of cardiac abnormalities in a group of
MM patients with different clinical phenotypes and to
test the additional diagnostic value of CMR in this pa-
tient population. Moreover, the hypothesis that different
neuromuscular MM syndromes present with different
cardiac disease phenotypes was evaluated.
Methods
Study population
Sixty-four patients with known MM were prospectively
enrolled between 2009 and 2014 as participants of the
“Mito-HERZ” study that was already described elsewhere
[18]. All patients underwent cardiac and neurological eval-
uations including multi-parametric CMR. The clinical
diagnosis of MM had been previously confirmed based on
molecular genetic testing and/or skeletal biopsy with ap-
propriate findings in all patients [10]. Exclusion criteria
were presence of claustrophobia and contraindications to
CMR or to gadolinium contrast administration.
Based on the clinical (neuromuscular) phenotype and
genetic findings, the patients were further grouped as
follows: (1) CPEO/KSS (N = 33; 29 with CPEO and 4
with KSS); (2) MELAS and MELAS–like (N = 11; 7 with
MELAS and 4 with MELAS-like); (3) MERRF (N = 3)
and (4) other non-specific MM forms (N = 17) (see also
Additional file 1). In addition, 25 healthy individuals
matched for age, gender and cardiovascular risk factors
with no history of cardiac disease were enrolled between
March 2011 and May 2014 and represented the control
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from the local ethics committee, and all participating pa-
tients provided written informed consent.Cardiac evaluation
Both MM patients and controls underwent cardiac work-
up including a thorough clinical history, physical examin-
ation, 12-lead ECG and CMR. An ECG was considered
abnormal whenever at least one of the following findings
was present: (1) arrhythmia; (2) conduction abnormalities;
(3) isolated ST-segment depression in two or more con-
tiguous leads; (4) isolated inverted T-waves; (5) pathologic
Q-waves; (6) a Sokolow-Lyon index > 35 mm as sign of LV
hypertrophy. In the MM patients, blood samples were
taken for laboratory analysis including total creatine kin-
ase (CK) and the cardiac biomarkers troponin T (TnT)
and brain natriuretic-peptide (NT-proBNP).CMR imaging protocol
ECG-gated CMR studies were performed on 1.5-T scan-
ners (Aera, Siemens Medical Solutions, Erlangen,
Germany and Achieva, Philips, Best, The Netherlands)
using commercially available cardiac software, electro-
cardiographic triggering, and cardiac-dedicated surface
coils. Cine-imaging was performed using a steady-state-
free-precession (SSFP) sequence in three long-axis slices
(four-, three- and two-chamber) and a stack of short-
axis slices completely covering the LV. LGE-imaging was
performed using a T1-weighted inversion recovery
gradient-echo sequence 10-15 min after intravenous
contrast administration (0.15 mmol/kg Magnevist®) in
the same imaging planes as the cine-images.CMR image analysis
CMR analysis was performed off-line by two experienced
readers. Ventricular volumes, ejection fraction and LV
mass were derived by contouring endo- and epicardial
borders on the short-axis cine images and indexed to body
surface area. The papillary muscles were included in the
LV cavity. LV hypertrophy was considered present when-
ever maximal end diastolic wall thickness was ≥ 13 mm in
men and ≥ 12 mm in women. The ratio of LV mass to
end-diastolic volume was used as an index of concentric
hypertrophy [20]. LGE presence and pattern were visually
assessed on the short-and long-axis images by using the
AHA 17-segment model. LGE pattern was globally
assessed as: ischemic (subendocardial and/or transmural)
and non-ischemic (subepicardial and/or intramural). An
abnormal CMR study was defined by: (1) a LV ejection
fraction (EF) less than 60 % and/or (2) the presence of un-
explained LV hypertrophy and/or (3) LGE presence in at
least one myocardial segment.Statistical analysis
Continuous variables with normal distribution are expressed
as mean ± SD. Categorical variables are expressed as fre-
quency with percentage. Student’s t-test was used for
comparison of normally distributed characteristics be-
tween MM patients and controls. Levene’s test was used
for testing equality of variances. One-way ANOVA with
Bonferroni post hoc correction was used for subgroup
multiple comparison analyses. Dunnett’s post hoc test was
used in the case of inequality of variances. The chi-square
test with Yate’s correction was used to compare non-
continuous variables expressed as proportions. Statistical
analysis was performed using SPSS software for Windows
(Version 19.0, IBM Corp., Armonk., NY). A p-value ≤ 0.05
was considered statistically significant.
Results
Patient characteristics
Demographic an main clinical characteristics of both pa-
tients and controls are shown in Table 1. Mean age was
50 ± 15 years for MM patients and 47 ± 12 years for con-
trols. With regard to age, there was no significant differ-
ence between MM subgroups (p = 0.46).
Twenty-six percent (N = 17) of the patients had a posi-
tive family history for MM. MELAS/-like patients pre-
sented significantly more often with a positive family
history compared to CPEO/KSS and other MM patients.
Thirty-one percent of MM patients (N = 20) had previ-
ously received a cardiac diagnosis as follows: arrhythmia
(N = 8), impaired LV systolic function (N = 5), LV hyper-
trophy (N = 3), coronary artery disease (other than in-
farct) (N = 3) and left bundle branch block (N = 1).
Although MELAS/-like patients had an almost double
rate of previous heart disease diagnosis compared to the
other MM subgroups, this difference was not statistically
significant.
Table 2 summarizes the frequencies of different clin-
ical features in MM patients. Nineteen percent of pa-
tients (N = 12) presented with chest pain symptoms and
47 % (N = 30) with exertional dyspnoea. Altogether, 48 %
of MM patients had symptoms of possible cardiac origin
at inclusion. No significant difference between MM
groups regarding cardiac symptoms frequency was noted
(p = 0.06 for any possible cardiac symptoms). Interest-
ingly, MELAS/-like patients were the least symptomatic
subgroup.
Laboratory results
As shown in Table 1, 13 % (N = 8) of the MM patients
showed an elevated TnT and 25 % (N = 16) elevated
natriuretic peptides at inclusion. Among the 11 CPEO/
KSS patients with elevated biomarkers, 10 had elevated
NT-proBNP and 1 elevated TnT levels. Six MELAS/-like
patients had an increase in biomarkers, TnT elevation














Age, yrs 50 ± 15 52 ± 14 44 ± 17 46 ± 3 50 ± 15 47 ± 12 0.45
Male, n (%) 28 (44) 12 (36) 3 (27) 2 (67) 11 (65) 12 (48) 0.22
Diabetes, n (%) 10 (16) 5 (15) 3 (27) 0 (0) 2 (12) 3 (12) 0.51
Hypertension, n (%) 10 (16) 6 (18) 0 (0) 0 (0) 4 (24) 5 (20) 0.79
MM family history, n (%) 17 (26) 4 (13)* 9 (80) 2 (67) 2 (13)* - <0.001
Previous cardiac diagnosis, n (%) 20 (31) 8 (24) 7 (64) 1 (33) 4 (24) - 0.09
BMI, kg/m2 24 ± 4 23 ± 4 22 ± 4 25 ± 3 25 ± 4 26 ± 4 0.07
Lab results
Elevated CK, n (%) 29 (45) 14 (42) 5 (46) 2 (67) 8 (47) - 0.89
Elevated TnT, n (%) 8 (13) 1 (3)* 5 (46) 1 (33) 1 (6)* - 0.003
Elevated NT-proBNP, n (%) 16 (25) 10 (30) 4 (36) 0 (0) 2 (11) - 0.29
Any elevated cardiac biomarkers, n (%) 21 (33) 11 (33) 6 (55) 1 (33) 3 (18) - 0.23
ECG findings
Sinus rhythm, n (%) 64 (100) 33 (100) 11 (100) 3 (100) 17 (100) 25 (100) 1.00
QRS abnormalities, n (%) 11 (17) 5 (15) 5 (46)§ 1 (33) 0 (0)* 2 (8) 0.01
ST/T abnormalities, n (%) 11 (17) 3 (9)* 8 (73)§ 0 (0) 0 (0)* 2 (8) <0.001
Any abnormal ECG findings, n (%) 18 (28) 8 (24)* 9 (82)§ 1 (33)* 0 (0)* 4 (16) <0.001
Medication
ACE inhibitor/ARB, n (%) 16 (25) 9 (27) 3 (20) 0 (0) 5 (29) 5 (20) 0.89
Beta blocker, n (%) 9 (14) 5 (15) 1 (10) 0 (0) 3 (18) 2 (8) 0.90
CoQ10, n (%) 23 (36) 10 (30) 6 (55) 1 (33) 6 (35) - 0.51
Creatin/Carnitin, n (%) 9 (14) 7 (21) 0 (0) 1 (33) 1 (6) - 0.16
Vitamins, n (%) 15 (24) 9 (27) 0 (0) 1 (33) 5 (31) - 0.15
MM – mithochondrial myopathy; BMI – body mass index; CK – creatine kinase; TnT – troponin T; ACE – angiotensin converting enzyme; ARB – angiotensin
receptor blocker; CoQ10 – coenzyme Q10
*- post Hoc p < 0.05 vs. MELAS/-like; § - vs. Control
Bold data indicates either significant or most important results
Table 2 Frequency of clinical features
N (%) Total MM Patients (N = 64) CPEO/KSS (N = 33) MELAS/-like (N = 11) MERRF (N = 3) Other MM (N = 17)
Chest pain symptoms 12 (19) 5 (15) 1 (10) 1 (33) 5 (29)
Exercise dyspnea 30 (47) 17 (52) 2 (18) 3 (100) 8 (47)
Any cardiac symptom 31 (48) 17 (52) 2 (18) 3 (100) 9 (53)
Skeletal myopathy 44 (69) 23 (70) 9 (82) 2 (67) 10 (59)
Encephalopathy 5 (8) 0 (0) 4 (36) 0 (0) 1 (6)
Seizures 5 (8) 0 (0) 3 (27) 1 (33) 1 (6)
Stroke-like episodes 5 (8) 0 (0) 4 (36) 0 (0) 1 (6)
Cognitive dysfunction 5 (8) 1 (3) 3 (27) 0 (0) 1 (6)
Hearing loss 10 (16) 5 (15) 4 (36) 0 (0) 1 (6)
Neuropathy 11 (16) 3 (9) 1 (9) 1 (33) 6 (35)
Sleeping apnea 3 (5) 1 (3) 0 (0) 1 (33) 1 (6)
Ptosis 32 (50) 25 (76) 1 (9) 2 (67) 4 (24)
Ophtalmoplegia 25 (39) 20 (61) 1 (9) 1 (33) 3 (18)
Retinopathy 6 (9) 3 (9) 2 (18) 0 (0) 1 (6)
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other MM patients showed significantly less frequently
TnT elevation when compared to MELAS/-like (p = 0.003).
One third (N = 21) of the MM patients had an increase in
at least one of the two cardiac biomarkers with no signifi-
cant difference between groups.
ECG findings
All patients and controls were in sinus rhythm at pres-
entation. QRS abnormalities were seen in 11 MM pa-
tients (left bundle branch block, N = 1; right bundle
branch block, N = 5; pathologic Q waves, N = 4 and LV
hypertrophy, N = 1) and in two controls (right bundle
branch block, N = 1 and left ventricular hypertrophy,
N = 1). Similarly, isolated ST/T abnormalities were ob-
served in 11 MM patients (ST-segment depression, N = 1
and T-wave inversion, N = 10) and in two controls (both
with T-wave inversion). Five of the CPEO/KSS patients with
abnormal ECG showed RBBB and 3 showed T-wave inver-
sions. In the 9 (82 %) MELAS/-like patients with abnormal
tracings, the following ECG abnormalities were found:
pathologic Q-waves in four, LV hypertrophy in one, LBBB
in one and ST/T changes in eight. In total, 18 (28 %) MM
patients showed abnormal ECG findings with significantly
more MELAS/-like patients presenting with pathological
ECGs compared to the other subgroups and to controls.
CMR findings compared to normal controls
The CMR findings for patients, including the different
MM subgroups and controls are listed in Tables 3-4. Com-





LV end-diastolic volume index ml/m2 67 ± 18 61 ± 14*§
LV end-systolic volume index, ml/m2 25 ± 2 21 ± 8*
LV mass index, g/m2 56 ± 23 49 ± 11*
LV ejection fraction, % 66 ± 8 66 ± 7
LV ejection fraction <60 %, n (%) 18 (28) 8 (24)
LV mass/ end-diastolic volume, g/ml 0.84 ± 0.27 0.84 ± 0.24
Max. wall thickness, mm 10 ± 3 9 ± 2*
LV hypertrophy in absence of AHT, n (%) 14 (22) 3 (9)*
RV end-diastolic volume index ml/m2 66 ± 14 63 ± 12
RV end-systolic volume index, ml/m2 30 ± 9 29 ± 9
RV ejection fraction, % 55 ± 10 55 ± 11
LGE presence, n (%) 21 (33) 12 (36)§
Non-ischemic LGE presence, n (%) 19 (30) 10 (30)§
Any abnormal CMR findings, n (%) 34 (53) 18 (55)
*- post Hoc p < 0.05 vs. MELAS/-like; § - vs. Control
LV – left ventricle; RV –right ventricle; AHT – arterial hypertension; LGE – late gadol
Bold data indicates either significant or most important resultssignificantly lower LV end-diastolic volumes (p = 0.028)
and increased maximal wall thickness (p = 0.005) with sig-
nificant more frequent LV hypertrophy (p = 0.016) and
higher concentricity as expressed by the ratio of LV mass
to end-diastolic volume (p < 0.0001).
For the subgroup analysis, when compared to controls
(Table 3), CPEO/KSS patients showed significantly lower
LV end-diastolic volumes and increased LV concentricity
without overt hypertrophy. On the other hand, in relation
to controls, MELAS/-like patients presented with increased
frequency of concentric hypertrophy with significantly lar-
ger wall thickness and LV mass to LV end-diastolic volume
index. No significant differences regarding functional pa-
rameters and hypertrophy were depicted for MERRF and
other MM when compared to controls.
Regarding LGE presence, 21 (33 %) of the MM patients
showed LGE in at least one myocardial segment, of which
19 (30 %) patients had non-ischemic patterns (16 intra-
mural and two subepicardial) and two patients (both with
CPEO) showed ischemic (subendocardial) LGE. Two pa-
tients with predominantly intramural LGE showed also
limited transmural extension. Among controls, one pa-
tient showed ischemic and none non-ischemic LGE. Com-
pared to controls, non-ischemic LGE was more frequently
depicted in MM patients (p = 0.001). This significant dif-
ference was primarily due to the higher LGE prevalence in
MELAS/-like (N = 8, 73 %) and secondly in CPEO/KSS
(N = 10, 30 %) patients, but not in the other two sub-
groups (MERRF and other MM).
Altogether, 34 (53 %) MM patients presented at least









85 ± 24 73 ± 15 66 ± 14* 76 ± 17 0.001
37 ± 20 28 ± 10 24 ± 7* 27 ± 8 0.002
90 ± 35 58 ± 17 50 ± 12* 50 ± 12* <0.001
59 ± 12 62 ± 5 65 ± 6 65 ± 5 0.09
6 (55) 1 (33) 3 (18) 2 (8) 0.07
*§ 1.07 ± 0.31§ 0.71 ± 0.06 0.72 ± 0.22* 0.67 ± 0.11 <0.001
14 ± 3§ 10 ± 2 10 ± 2* 8 ± 2 <0.001
9 (82)§ 1 (33) 1 (6)* 0 (0)* <0.001
69 ± 18 65 ± 9 72 ± 15 72 ± 18 0.21
30 ± 10 32 ± 7 33 ± 10 31 ± 9 0.49
57 ± 8 51 ± 5 54 ± 10 57 ± 8 0.70
8 (73)§ 0 (0) 1 (6)* 1 (4) <0.001
* 8 (73)§ 0 (0) 1 (6)* 0 (0) <0.001
10 (91) 1 (33) 5 (29) 3 (12) <0.001
inium enhancement; CMR – cardiac magnetic resonance
Table 4 CMR findings (without controls)
Total (N = 64) CPEO/KSS (N = 33) MELAS/-like (N = 11) MERRF (N = 3) Other MM (N = 17) p value
LV end-diastolic volume index ml/m2 67 ± 18 61 ± 14* 85 ± 24 73 ± 15 66 ± 14* 0.002
LV end-systolic volume index, ml/m2 25 ± 2 21 ± 8 37 ± 20 28 ± 10 24 ± 7 0.003
LV mass index, g/m2 56 ± 23 49 ± 11* 90 ± 35 58 ± 17 50 ± 12* <0.001
LV ejection fraction, % 66 ± 8 66 ± 7 59 ± 12 62 ± 5 65 ± 6 0.09
LV ejection fraction <60 %, n (%) 18 (28) 8 (24) 6 (55) 1 (33) 3 (18) 0.26
LV mass/ end-diastolic volume, g/ml 0.84 ± 0.27 0.84 ± 0.24 1.07 ± 0.31 0.71 ± 0.06 0.72 ± 0.22* 0.008
LV hypertrophy in absence of AHT, n (%) 14 (22) 3 (9)* 9 (82) 1 (33) 1 (6)* <0.001
RV end-diastolic volume index ml/m2 66 ± 14 63 ± 12 69 ± 18 65 ± 9 72 ± 15 0.22
RV end-systolic volume index, ml/m2 30 ± 9 29 ± 9 30 ± 10 32 ± 7 33 ± 10 0.39
RV ejection fraction, % 55 ± 10 55 ± 11 57 ± 8 51 ± 5 54 ± 10 0.75
LGE presence, n (%) 21 (33) 12 (36) 8 (73) 0 (0) 1 (6)* 0.001
Non-ischemic LGE presence, n (%) 19 (30) 10 (30)* 8 (73) 0 (0) 1 (6)* <0.001
Any abnormal CMR findings, n (%) 34 (53) 18 (55)* 10 (91) 1 (33) 5 (29)* 0.007
*- post Hoc p < 0.05 vs. MELAS/-like
Bold data indicates either significant or most important results
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pathological CMR in 91 % (N = 10) and CPEO/KSS pa-
tients in 55 % (N = 18) of cases, respectively – which was
significantly higher compared to the controls. As illus-
trated in Table 5, cardiac involvement was most frequently
diagnosed by a comprehensive CMR study comprising
cine- and LGE-images (in 53 %) and rather infrequently
based on ECG or cardiac biomarkers, respectively (in
28 % and 33 %, p = 0.008).
CMR pattern according to MM syndrome and relationship
to other diagnostic tools
CPEO/KSS
A predominantly intramural pattern of enhancement was
noted in 8/10 (80 %) CPEO/KSS patients with proof of
non-ischemic LGE (basal inferolateral distribution in six
and basal to midventricular septal pattern in two; Fig. 1). A
subepicardial pattern was found in the remaining two with
basal inferolateral location in both. The three patients with
LV hypertrophy in the absence of arterial hypertension or
other causal reasons presented only isolated mild septal





Any (possibly) cardiac symptoms 31 (48) 17 (52)
Elevated TnT or NT-proBNP 21 (33) 11 (33)
Any abnormal ECG findings 18 (28) 8 (24)*
LV ejection fraction <60 %, n (%) 18 (28) 8 (24)
LGE presence, n (%) 21 (33) 12 (36)§
Any abnormal CMR findings, n (%) 34 (53) 18 (55)§
*- post Hoc p < 0.05 vs. MELAS/-like; § - vs. Control
Bold data indicates either significant or most important resultsischemic LGE presence or an abnormal CMR finding and
an abnormal ECG (p = 0.67 and p = 0.23, respectively).
Moreover, there was no significant difference in the occur-
rence of elevated cardiac biomarkers between patients with
(N = 18) and without (N = 15) abnormal CMR findings
(29 % vs. 38 %, p = 0.72) among CPEO/KSS patients.
MELAS/-like
In comparison to CPEO/KSS, MELAS/-like patients
showed significantly larger LV mass with increased LV
end-diastolic volumes. Left ventricular hypertrophy was
also more frequently encountered in this subgroup com-
pared to CPEO/KSS. Particularly, a concentric pattern
was noted in six out of nine (67 %) patients with LV
hypertrophy. In addition, MELAS/-like patients showed
higher rates for non-ischemic (predominantly intra-
mural) LGE compared to CPEO/KSS. Moreover, a more
heterogeneous distribution and extent of LGE, poten-
tially appearing in any of the myocardial segments and
occupying between one and 16 segments was observed
in MELAS/-like patients (Fig. 2). Furthermore, a signifi-









2 (18) 3 (100) 9 (53) -
6 (55) 1 (33) 3 (18) - 0.227
9 (82)§ 1 (33)* 0 (0)* 2 (8) <0.001
6 (55) 1 (33) 3 (18) 2 (8) 0.072
8 (73)§ 0 (0) 1 (6)* 1 (6) <0.001
10 (91)§ 1 (33) 5 (29) 3 (12) <0.001
A B
C D
Fig. 1 Cine-CMR images in long-axis (a) and short-axis views (b) with
corresponding late gadolinium enhancement (LGE) images (c-d).
A diffuse intramural pattern of LGE is seen in the basal inferolateral
wall segments of the left ventricle (red arrows)
A
C
Fig. 2 Cine-CMR images in long-axis (a) and short-axis views (b) with corre
non-ischemic, patchy pattern of LGE is seen in almost all segments of the
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ischemic LGE (100 % vs. 33 %, p = 0.050) could be noted.
Moreover, the majority of patients (6/10) with abnormal
CMR findings presented with elevated cardiac bio-
markers; the only MELAS patient with a normal CMR
showed no increase in biomarkers.
MERRF
Among the three MERRF patients only one showed
pathological CMR findings with a mildly impaired LV
ejection fraction and mild septal hypertrophy, however,
without presence of LGE. The same patient presented a
RBBB and mild TnT elevation.
Other MM
As shown in Table 3, among patients with other MM
forms (N = 17) only one showed presence of LGE (intra-
mural pattern, location basal inferolateral) associated
with mild septal hypertrophy. This LGE-positive patient
also demonstrated a mild TnT elevation. Additionally, a
mildly impaired LV ejection fraction was found in three
patients, in two as an isolated finding and in one associ-
ated with mild septal hypertrophy. Another patient
showed only isolated mild septal hypertrophy.
Discussion
Our study presents cross-sectional CMR data in a large
cohort of adult patients with MM. We evaluated the
presence and pattern of cardiomyopathy and could showB
D
sponding late gadolinium enhancement (LGE) images (c-d). A diffuse,
left ventricle (red arrows)
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patients (53 %) with a non-ischemic LGE pattern being
the most frequently encountered finding; (2) at least two
different patterns of cardiac involvement can be distin-
guished, one in CPEO/KSS patients with intramural
LGE in the basal inferolateral wall and a second one in
MELAS/-like patients with overt concentric hypertrophy
and intramural, diffusely located LGE, (3) in both
CPEO/KSS and MELAS/-like patients CMR was super-
ior in diagnosing cardiomyopathy compared to ECG and
cardiac biomarkers, with a particular diagnostic benefit
in CPEO/KSS patients.
CMR abnormalities
Even though MM-related cardiomyopathy was described
in a series of reports, to the best of our knowledge the
current work is the first to show that, by means of CMR,
structural and/or functional abnormalities are present in
the majority of MM patients [4, 6, 9, 10, 13, 14, 16–18].
Moreover, the present study is the first that consistently
demonstrates the presence of a concentric hypertrophic
remodelling pattern in MELAS/-like patients (and a ten-
dency in CPEO/KSS patients) [9, 17]. This remodelling
pattern resembles the myocardial changes found in other
inherited systemic disorders not associated with respira-
tory chain dysfunction such as Friedreich’s ataxia
[21–24]. In Friedreich’s ataxia, such a remodelling pat-
tern is generally considered to occur secondary to adap-
tive changes in response to an impaired cellular energy
metabolism which is caused by mitochondrial structural
abnormalities [7, 25, 26]. In MELAS, for example, histo-
logical examinations of endomyocardial biopsy specimens
showed mitochondrial alterations with enlargement and
accumulation and, secondarily, disperse interstitial fibrosis
and partial myocardial disarray [7, 13, 15]. Considering
that one third of MM patients presented with non-
ischemic LGE in the present study, CMR represents a new
possibility to detect myocardial tissue damage in vivo be-
yond the known features of LV remodelling and functional
abnormalities in this population [13–15, 18, 27].
CMR-based phenotype patterns in different MM syndromes
Whereas in the few patients with MERRF and in those
with other MM no particular CMR changes were found,
two potentially characteristic patterns were depicted in
CPEO/KSS and MELAS/-like patients, respectively. First,
a tendency towards concentric remodelling was noted in
CPEO/KSS and second, an overt concentric hypertrophy
in addition to LV systolic dysfunction (in half of the cases)
was observed in MELAS/-like patients. At first view, these
differences could be simply the consequence of a more
severe cardiac involvement in MELAS/-like syndrome.
Yet, interestingly, despite the known degree of neuromus-
cular phenotype overlap between syndromes, we found nooverlap in cardiac pattern between the two syndromes
[1]. Moreover, this difference becomes more prominent
when looking at myocardial damage - as depicted by
LGE-imaging.
As already reported previously, CPEO/KSS patients tend
to show intramural LGE in the inferolateral wall that
might either be due to an unequal and predominant distri-
bution of mitochondrial energy deficiency in this area
and/or due to an increased mechanical stress in the infer-
olateral wall [18]. In contrast, MELAS/-like patients do
not only frequently show the presence of LGE, but the
pattern of LGE is also completely different (Figs. 1-2):
strong intramural LGE with focal (and rather patchy) ac-
centuation extending in some cases over all myocardial
segments. Besides replacement fibrosis secondary to per-
turbations in cell energy metabolism with consecutive cell
death, another interesting mechanism might be involved
in this unusual pattern of LGE seen in MELAS patients
(Fig. 2): Similar to the pathogenesis of stroke like cerebral
lesions, a hallmark of the MELAS syndrome, a mitochon-
drial angiopathy with consecutive vasogenic edema and
fluid extravasation could be the mechanism for LGE for-
mation in the myocardium [11, 13, 16, 28]. This theory is
further supported by the observed presence of myocardial
edema as well as perfusion defects in areas with LGE in
some of these patients - but not in LGE-positive areas
from CPEO/KSS patients [13, 14].
Interestingly, despite the data suggesting a higher
prevalence of arterial hypertension in MELAS as ad-
junctive cause of hypertrophy, none of our MELAS/-like
patients had elevated blood pressure [29]. A clear ex-
planation of the exact pathophysiology of these two pat-
terns cannot be given and is beyond the purpose of this
paper, but our findings demonstrate that despite the
variability in phenotype within each of the two syn-
dromes, relatively specific patterns of cardiomyopathy
can be depicted for both.
Additional value of CMR in the cardiac work-up
First, CMR was superior to the ECG as well as to the
measurement of cardiac biomarkers regarding the detec-
tion of (signs of) cardiomyopathy for both the whole study
group and individual subgroups. Although ECG abnor-
malities are quite common and are sometimes seen early
in the MM disease course, they are mostly unspecific [4,
8, 30]. For example, in a mixed MM population including
CPEO and MELAS, Limongelli et al. described ECG
changes in 68 % of cases ranging from pre-excitation to
conduction abnormalities and ST/T changes [4]. Similarly,
in our MM population ECG abnormalities were multifa-
ceted. Moreover, they did not relate to the functional and/
or structural CMR findings in CPEO/KSS and found only
a weak relationship in MELAS/-like patients. Particularly
in CPEO/KSS, approximately one third of the patients
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Second, even though echocardiography was not rou-
tinely performed in the current study, we consider that
CMR has a clear advantage over echocardiography for
the diagnosis of cardiomyopathy in these patients: The
superiority of CMR comes mainly from its ability to sen-
sitively and reproducibly detect structural tissue changes
with the depiction of subtle myocardial damage by LGE-
imaging [18, 31]. Notably, in 15 % of the CPEO/KSS
patients LGE was the only pathological CMR finding.
Further, as shown by Pfeffer et al. in a follow-up study
conducted in CPEO patients with an initial normal car-
diac work-up, only one of the fifteen patients developed
new ECG and/or echocardiographic abnormalities over
five years making the detection of cardiomyopathy by
these techniques even less probable [10]. Therefore, we
suggest that a CMR study should be part of the diagnos-
tic approach of cardiomyopathy in MM patients. Early
detection of cardiac disease is a prerequisite for the
implementation of successful therapeutic strategies and
appropriate risk stratification with timing of follow-up
studies. In this context, the recently published ESC guide-
lines for the management of hypertrophic cardiomyopathy
also address mitochondrial diseases such as MELAS and
suggest to perform a CMR study at initial presentation
if local expertise in this technique is available [32]. We ad-
vocate that CMR should be considered in all patients with
MM at their baseline assessment – if local resources and
expertise permit it. Moreover, we suggest that CMR
follow-up studies in MM patients with pathological CMR
results (particularly with presence of LGE and/or impaired
systolic function) and potentially progressive disease –
particularly those with MELAS and MELAS-like disease -
should be considered every 6-12 months while a follow-up
study every 4-5 years will be sufficient in (adult) patients
with no involvement of the heart muscle.
In MM patients with a rather hypertrophic pattern of
cardiomyopathy (e.g. MELAS or MELAS-like patients),
ß-blockers, angiotensin-converting enzyme (ACE) inhibi-
tors and angiotensin receptor blockers may potentially help
to (at least) slow down the progression of cardiomyopathy
– as was shown in aetiologically different forms of HCM
[32]. In this context, it should be emphasized that MM
such as MELAS and MELAS-like diseases are mentioned
as specific HCM forms in the recently published “2014 ESC
guidelines on diagnosis and management of HCM”.
CMR may not only help to accurately assess the thickness
of the LV wall, but the mere presence of LGE in e.g. MELAS
patients may precede the occurrence of LV hypertrophy and
thereby used as a diagnostic tool for a timely initiation of
the aforementioned treatment options – prior to the occur-
rence of LV hypertrophy and advanced myocardial scarring.
Our own (unpublished preliminary) experiences suggest thatcardiac disease progression regarding myocardial scarring
occurs surprisingly fast in some patients with MELAS or
MELAS-like diseases. Therefore, the most accurate diag-
nostic tools available should be used in order to detect the
first signs of cardiomyopathy.
Paralleling other genetic cardiomyopathies, e.g. hyper-
trophic cardiomyopathy, non-ischemic LGE detection
could play an additional prognostic role in the risk stratifi-
cation of MM, particularly in MELAS patients [33–35]. It
has been already shown that MELAS patients have a high
incidence of cardiac death as well as arrhythmia and heart
failure events, primarily related to LV hypertrophy [2, 3].
Since our preliminary experiences in MELAS/-like pa-
tients point to a rather disproportionately extensive pat-
tern of LGE compared to the degree of LV hypertrophy
(Fig. 1), one may even hypothesize that detection of LGE
in these patients could have a superior prognostic value
than in other non-MM diseases that are associated with
LV hypertrophy. However, this issue is a clinically relevant
topic for future research and so far, there are no follow-up
data involving LGE-CMR in MM patients.
Limitations
The first limitation is the small number of patients, par-
ticularly suffering from MERRF. This fact obviously limits
us to draw appropriate conclusions regarding presence,
pattern and clinical value of cardiomyopathy in these pa-
tients. A recent study from Wahbi et al. found cardiac ab-
normalities in 44 % of the 18 MERRF patients included
comprising LV dilatation or hypertrophy with or without
systolic dysfunction [12]. A direct comparison to our data
is difficult as this study used echocardiography and other
definitions for LV hypertrophy and dilatation.
A second limitation is the absence of histopathological
data. The patients did not fulfil the current guideline
recommendations for performing EMB and therefore,
this procedure was rarely performed [36].
A third limitation lies in the fact that controls were
free from cardiac symptoms while MM patients were
symptomatic at inclusion. Nevertheless, in MM patients
cardiac symptoms are often unspecific and rather diffi-
cult to differentiate from the coexisting neuromuscular
disease. Moreover, no association between symptoms
and CMR findings was found.
Conclusion
Cardiac involvement is a frequent finding in MM pa-
tients – and particularly present in KSS/CPEO as well as
MELAS/-like patients. Despite a high variability in clin-
ical presentation, CPEO/KSS patients typically show an
intramural pattern of LGE in the basal inferolateral wall
whereas MELAS patients are characterized by overt con-
centric hypertrophy and a rather unique, focally accentu-
ated and diffusely distributed LGE.
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